(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Weight-loss pill approval set to accelerate food industry product overhauls- No injuries after blast at pro-Israel centre in the Netherlands
- People are getting their news from AI – and it’s altering their views
- California officials warn against foraging wild mushrooms after deadly poisoning outbreak
- Don't miss these five impressive spots in Bangkok
- What will happen if Artemis 2 astronauts get hit by a solar storm during NASA's ambitious moon mission?
- How to get tickets to Jay-Z’s sold out Yankee Stadium shows
- The most effective method to Comprehend the Variables Affecting Medical attendant Pay rates
- Netanyahu leads meeting on West Bank riots, Katz defends axing administrative detention for Jews
